207 related articles for article (PubMed ID: 12216949)
21. Some clinical consequences of red cell incompatibility: the Bradshaw lecture 1978.
Mollison PL
J R Coll Physicians Lond; 1979 Jan; 13(1):15-20. PubMed ID: 105132
[TBL] [Abstract][Full Text] [Related]
22. Prediction of the severity of haemolytic disease of the newborn. Quantitative IgG anti-D subclass determinations explain the correlation with functional assay results.
Garner SF; Gorick BD; Lai WY; Brown D; Taverner J; Hughes-Jones NC; Contreras M; Lubenko A
Vox Sang; 1995; 68(3):169-76. PubMed ID: 7625074
[TBL] [Abstract][Full Text] [Related]
23. The role of the fetal immune system in the pathogenesis of RhD-hemolytic disease of newborns.
Gurevich P; Erina S; Gershon S; Zusman I
Hum Antibodies; 1997; 8(2):76-89. PubMed ID: 9289392
[TBL] [Abstract][Full Text] [Related]
24. Destruction of IgG anti-A sensitized erythrocytes by mononuclear leucocytes from normal and ABO haemolytic disease affected infants.
Romano EL; Rossi Devivo ML; Soyano A; Linares J
Clin Exp Immunol; 1984 Feb; 55(2):451-8. PubMed ID: 6538121
[TBL] [Abstract][Full Text] [Related]
25. Maternal antibodies against fetal blood group antigens A or B: lytic activity of IgG subclasses in monocyte-driven cytotoxicity and correlation with ABO haemolytic disease of the newborn.
Brouwers HA; Overbeeke MA; Ouwehand WH; Keuning K; van Ertbruggen I; van Leeuwen EF; Stoop JW; Engelfriet CP
Br J Haematol; 1988 Dec; 70(4):465-9. PubMed ID: 3219297
[TBL] [Abstract][Full Text] [Related]
26. Red Blood Cell Alloimmunization in the Pregnant Patient.
Webb J; Delaney M
Transfus Med Rev; 2018 Oct; 32(4):213-219. PubMed ID: 30097223
[TBL] [Abstract][Full Text] [Related]
27. Haemolytic disease of the fetus and newborn.
de Haas M; Thurik FF; Koelewijn JM; van der Schoot CE
Vox Sang; 2015 Aug; 109(2):99-113. PubMed ID: 25899660
[TBL] [Abstract][Full Text] [Related]
28. A case of unexplained mild Rh (D) haemolytic disease in utero.
Bromilow IM; Downing I; Walkinshaw SA; Welch CR; Duguid JK
Transfus Med; 1995 Mar; 5(1):31-5. PubMed ID: 7767395
[TBL] [Abstract][Full Text] [Related]
29. Transplacental IgG subclass concentrations in pregnancies at risk of haemolytic disease of the newborn.
Lubenko A; Contreras M; Rodeck CH; Nicolini U; Savage J; Chana H
Vox Sang; 1994; 67(3):291-8. PubMed ID: 7863629
[TBL] [Abstract][Full Text] [Related]
30. PREVENTION OF RH-HAEMOLYTIC DISEASE: A THIRD REPORT.
WOODROW JC; CLARKE CA; DONOHOE WT; FINN R; MCCONNELL RB; SHEPPARD PM; LEHANE D; RUSSELL SH; KULKE W; DURKIN CM
Br Med J; 1965 Jan; 1(5430):279-83. PubMed ID: 14229706
[No Abstract] [Full Text] [Related]
31. Monoclonal anti-D development programme.
Kumpel BM
Transpl Immunol; 2002 Aug; 10(2-3):199-204. PubMed ID: 12216950
[TBL] [Abstract][Full Text] [Related]
32. Results of tests with different cellular bioassays in relation to severity of RhD haemolytic disease. Report from nine collaborating laboratories.
Vox Sang; 1991; 60(4):225-9. PubMed ID: 1926829
[TBL] [Abstract][Full Text] [Related]
33. [Serum ABO immune antibodies in 1944 pregnant women].
Wan MR
Zhonghua Fu Chan Ke Za Zhi; 1991 Jan; 26(1):12-4, 60-1. PubMed ID: 1900749
[TBL] [Abstract][Full Text] [Related]
34. Clinical aspects of Rh immunization. Philip Levine Award Address.
Mollison PL
Am J Clin Pathol; 1973 Sep; 60(3):287-301. PubMed ID: 4199486
[No Abstract] [Full Text] [Related]
35. [Two neonates with severe rhesus antagonism inspite of low values in recent tests of antibody dependent cellular cytotoxicity (ADCC)].
Janssens LP; Koolen AM; Oei SG; Overbeeke MA
Ned Tijdschr Geneeskd; 1999 Sep; 143(36):1823-6. PubMed ID: 10526587
[TBL] [Abstract][Full Text] [Related]
36. Transfusion support in the management of immune haemolytic disorders.
Plapp FV; Beck ML
Clin Haematol; 1984 Feb; 13(1):167-83. PubMed ID: 6327130
[No Abstract] [Full Text] [Related]
37. Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17.
Denomme GA; Ryan G; Seaward PG; Kelly EN; Fernandes BJ
Transfusion; 2004 Sep; 44(9):1357-60. PubMed ID: 15318861
[TBL] [Abstract][Full Text] [Related]
38. The use of interferon-gamma-treated U937 cells in chemiluminescence assays to detect red cell, platelet and granulocyte antibodies of potential clinical significance.
Hadley AG; Poole GD; Amphlett NW; Lucas GF
Clin Lab Haematol; 1992; 14(4):315-26. PubMed ID: 1478011
[TBL] [Abstract][Full Text] [Related]
39. Antenatal tests in the diagnosis and assessment of severity of haemolytic disease (Hd) of the fetus and newborn (hdn).
Contreras M
Vox Sang; 1994; 67 Suppl 3():207-10. PubMed ID: 7975494
[No Abstract] [Full Text] [Related]
40. In vivo studies of monoclonal anti-D and the mechanism of immune suppression.
Kumpel BM
Transfus Clin Biol; 2002 Jan; 9(1):9-14. PubMed ID: 11889904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
